Contrasting Constellation Pharmaceuticals (CNST) and Its Competitors
Constellation Pharmaceuticals (NASDAQ: CNST) is one of 548 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Constellation Pharmaceuticals to related companies based on the strength of its dividends, earnings, valuation, profitability, risk, analyst recommendations and institutional ownership.
This is a summary of current ratings and target prices for Constellation Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Constellation Pharmaceuticals Competitors||4553||13028||27681||994||2.54|
Earnings and Valuation
This table compares Constellation Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Constellation Pharmaceuticals||N/A||-$59.92 million||-2.46|
|Constellation Pharmaceuticals Competitors||$2.15 billion||$228.73 million||-3.55|
Constellation Pharmaceuticals’ competitors have higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Constellation Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Constellation Pharmaceuticals Competitors||-1,760.46%||-120.17%||-28.09%|
Institutional and Insider Ownership
60.0% of Constellation Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Constellation Pharmaceuticals beats its competitors on 7 of the 12 factors compared.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.